Geoffrey Koff, MD
Pulmonary Disease · Drexel Hill, PANPI 1508090325
Payments from drug & device makers
Across 312 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Mylan Specialty L.p.$504
- Boehringer Ingelheim$494
- Regeneron Healthcare Solutions, Inc.$334
- ANI Pharmaceuticals, Inc.$288
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,028100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $1,625 |
| GSK | 61 | $1,092 |
| Mylan Specialty L.p. | 27 | $504 |
| Boehringer Ingelheim | 18 | $494 |
| Regeneron Healthcare Solutions, Inc. | 13 | $334 |
| ANI Pharmaceuticals, Inc. | 12 | $288 |
| Jazz Pharmaceuticals Inc. | 12 | $274 |
| Harmony Biosciences LLC | 24 | $246 |
| Philips North America LLC | 9 | $241 |
| Inari Medical, Inc. | 1 | $209 |
| Insmed, Inc. | 7 | $182 |
| Mallinckrodt Hospital Products Inc. | 6 | $158 |
| AbbVie | 2 | $147 |
| Novartis | 6 | $131 |
| Electromed, Inc. | 6 | $117 |
| Axsome Therapeutics, Inc. | 4 | $115 |
| Grifols USA, LLC | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Amgen | 3 | $76 |
| Verona Pharma, Inc. | 3 | $66 |
| Genentech USA, Inc. | 4 | $66 |
| Pfizer | 4 | $63 |
| Lilly USA, LLC | 2 | $59 |
| Inogen, Inc. | 2 | $55 |
| Sanofi | 3 | $53 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Merck | 2 | $30 |
| Viatris Specialty LLC | 1 | $29 |
| Baxter Healthcare | 1 | $27 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Aero US Inc | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Circassia Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$243
- FLOWTRIEVER CATHETER, S$209
- CT THROMBECTOMY SYSTEM KIT$209
- inCourage$143
- Rinvoq$120
- OFEV$113
How this compares
$7,040 in reported general payments places this provider in the 70th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 341 | $317,921 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 88 | $85,172 |
| Dupixent PenDupilumab | 20 | $78,138 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 143 | $76,328 |
| Breo ElliptaFluticasone/Vilanterol | 125 | $63,543 |
| Advair HfaFluticasone Propion/Salmeterol | 72 | $33,517 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 45 | $32,970 |
| Spiriva RespimatTiotropium Bromide | 31 | $27,405 |
| Incruse ElliptaUmeclidinium Bromide | 43 | $25,133 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 110 | $20,009 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $8,864 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 45 | $7,509 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $5,267 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 186 | $3,594 |
| Roflumilast | 46 | $3,539 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,092 | $482,925652 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,625 | $94,035118 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $494 | $60,37476 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Drexel Hill
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
- Tariq CheemaPittsburgh$907K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.